In vitro maintenance of FOXP3+Treg cells phenotype, epigenetics and function stability in humans – MAINTREG
FOXP3 expressing regulatory CD4+ T (Treg) cells are instrumental for the maintenance of self-tolerance. Treg cell therapy has a promising potential for the treatment of autoimmune diseases or for the induction of operational tolerance in solid organ transplantation. However human Treg cells are unstable in term of FOXP3 expression, specific epigenetics and suppressive function in vitro and in vivo. By next gen methods combining surface markers and transcriptome simultaneous translationnal analysis of Treg cells at the single cell level, in various settings including IPEX disease our ongloing phase I Treg cell therapy trial in liver and kidney transplantion, in vitro developping CAR-Treg cells and thymic Treg cells, we can determine targetable factors that are responsible for this instability and therefore aim at proposing fully optimized GMP expansion protocol for Treg cell expansion for cell therapy.
Project coordination
Makoto Miyara (CIMI Paris)
The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.
Partner
DMU SAPERE DMU APHP.Sorbonne : Spécialités Abdomino-PElviennes et Rénales de l’Adulte et de l’Enfant
HIPI Human Immunology, Pathophysiology and Immunotherapy / Immunologie humaine, physiopathologie & immunithérapie
CIMI CIMI Paris
IMAGINE INSTITUT DES MALADIES GÉNÉTIQUES (IHU)
HIPI Human Immunology, Pathophysiology and Immunotherapy / Immunologie humaine, physiopathologie & immunithérapie
Help of the ANR 612,528 euros
Beginning and duration of the scientific project:
September 2021
- 48 Months
